Utilizing yeast chemogenomic profiles for the prediction of pharmacogenomic associations in humans

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Silberberg, Yael ^a   Kupiec, Martin ^a   Sharan, Roded ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MODEL; DRUG EFFECTS; FUNGAL GENOME; GENETICS; HUMAN; PHARMACOGENETICS; PRECLINICAL STUDY; PROCEDURES; SACCHAROMYCES CEREVISIAE;

DRUG EVALUATION, PRECLINICAL; GENOME, FUNGAL; HUMANS; MODELS, BIOLOGICAL; PHARMACOGENETICS; SACCHAROMYCES CEREVISIAE;

EID: 84964000486     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep23703     Document Type: Article

References (46)

1. Ginsburg, G. S., McCarthy, J. J. Personalized medicine: revolutionizing drug discovery and patient care. Trends Biotechnol. 19, 491-496 (2001).
2. Payami, H., Factor, S. A. Promise of Pharmacogenomics for Drug Discovery, Treatment and Prevention of Parkinson's Disease. A Perspective. Neurotherapeutics 11, 111-116 (2014).
3. Evans, W. E., Relling, M. V. Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics. Science 286, 487-491 (1999).
4. Goodman, T., Ferro, A., Sharma, P. Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br. J. Clin. Pharmacol. 66, 222-232 (2008).
5. Arranz, M. J., de Leon, J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol. Psychiatry 12, 707-747 (2007).
6. Biernacka, J. M. et al. Pharmacogenomics of antidepressant induced mania: A review and meta-analysis of the serotonin transporter gene (5HTTLPR) association. J. Affect. Disord. 136, e21-e29 (2012).
7. Whirl-Carrillo, M. et al. Pharmacogenomics knowledge for personalized medicine. Clin. Pharmacol. Ther. 92, 414-417 (2012).
8. Welter, D. et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res. 42, D1001-1006 (2014).
9. Hansen, N. T., Brunak, S., Altman, R. B. Generating genome-scale candidate gene lists for pharmacogenomics. Clin. Pharmacol. Ther. 86, 183-189 (2009).
10. Funk, C. S., Hunter, L. E., Cohen, K. B. Combining heterogenous data for prediction of disease related and pharmacogenes. Pac. Symp. Biocomput. Pac. Symp. Biocomput. 328-339 (2014).
11. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607 (2012).
12. Lamb, J. et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929-1935 (2006).
13. Giaever, G. et al. Genomic profiling of drug sensitivities via induced haploinsufficiency. Nat. Genet. 21, 278-283 (1999).
14. Lopez, A., Parsons, A. B., Nislow, C., Giaever, G., Boone, C. Chemical-genetic approaches for exploring the mode of action of natural products. Prog. Drug Res. Fortschritte Arzneimittelforschung Prog. Rech. Pharm. 66, 237, 239-271 (2008).
15. Parsons, A. B. et al. Integration of chemical-genetic and genetic interaction data links bioactive compounds to cellular target pathways. Nat. Biotechnol. 22, 62-69 (2004).
16. Ericson, E. et al. Off-Target Effects of Psychoactive Drugs Revealed by Genome-Wide Assays in Yeast. PLoS Genet 4, e1000151 (2008).
17. Hillenmeyer, M. E. et al. The chemical genomic portrait of yeast: uncovering a phenotype for all genes. Science 320, 362-365 (2008).
18. Lee, A. Y. et al. Mapping the cellular response to small molecules using chemogenomic fitness signatures. Science 344, 208-211 (2014).
19. Hoepfner, D. et al. High-resolution chemical dissection of a model eukaryote reveals targets, pathways and gene functions. Microbiol. Res. 169, 107-120 (2014).
20. Law, V. et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 42, D1091-1097 (2014).
21. Frolkis, A. et al. SMPDB: The Small Molecule Pathway Database. Nucleic Acids Res. 38, D480-487 (2010).
22. Pletscher-Frankild, S., Palleja, A., Tsafou, K., Binder, J. X., Jensen, L. J. DISEASES: Text mining and data integration of disease-gene associations. Methods 74, 83-89 (2015).
23. Kirchheiner, J. et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry 9, 442-473 (2004).
24. Kostev, K., Rex, J., Eith, T., Heilmaier, C. Which adverse effects influence the dropout rate in selective serotonin reuptake inhibitor (SSRI) treatment? Results for 50,824 patients. GMS Ger. Med. Sci. 12 (2014).
25. Hansen, R. A., Gartlehner, G., Lohr, K. N., Gaynes, B. N., Carey, T. S. Efficacy and Safety of Second-Generation Antidepressants in the Treatment of Major Depressive Disorder. Ann. Intern. Med. 143, 415-426 (2005).
26. Ruhé, H. G., Huyser, J., Swinkels, J. A., Schene, A. H. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J. Clin. Psychiatry 67, 1836-1855 (2006).
27. Schneider, L. S., Small, G. W., Clary, C. M. Estrogen Replacement Therapy and Antidepressant Response to Sertraline in Older Depressed Women. Am. J. Geriatr. Psychiatry 9, 393-399 (2001).
28. Schneider, L. S. et al. Estrogen Replacement and Response to Fluoxetine in a Multicenter Geriatric Depression Trial. Am. J. Geriatr. Psychiatry 5, 97-106 (1997).
29. Joffe, H., Cohen, L. S. Estrogen, serotonin, and mood disturbance: where is the therapeutic bridge? Biol. Psychiatry 44, 798-811 (1998).
30. Licinio, J. et al. Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans. Mol. Psychiatry 9, 1075-1082 (2004).
31. López-León, S. et al. Meta-analyses of genetic studies on major depressive disorder. Mol. Psychiatry 13, 772-785 (2008).
32. Lin, E. et al. Interaction of serotonin-related genes affects short-term antidepressant response in major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 33, 1167-1172 (2009).
33. Powzaniuk, M. et al. The LATS2/KPM tumor suppressor is a negative regulator of the androgen receptor. Mol. Endocrinol. Baltim. Md 18, 2011-2023 (2004).
34. Bartkova, J. et al. DNA damage response mediators MDC1 and 53BP1: constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours. Oncogene 26, 7414-7422 (2007).
35. Patel, A. N. et al. Mediator of DNA damage checkpoint protein 1 (MDC1) expression as a prognostic marker for nodal recurrence in early-stage breast cancer patients treated with breast-conserving surgery and radiation therapy. Breast Cancer Res. Treat. 126, 601-607 (2011).
36. Rokhlin, O. W. et al. MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer. Cancer Biol. Ther. 7, 1288-1296 (2008).
37. Kapitzky, L. et al. Cross-species chemogenomic profiling reveals evolutionarily conserved drug mode of action. Mol. Syst. Biol. 6, 451 (2010).
38. Rodriguez-Suarez, R. et al. Mechanism-of-action determination of GMP synthase inhibitors and target validation in Candida albicans and Aspergillus fumigatus. Chem. Biol. 14, 1163-1175 (2007).
39. Baba, T. et al. Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection. Mol. Syst. Biol. 2, 2006-8 (2006).
40. Butcher, R. A. et al. Microarray-based method for monitoring yeast overexpression strains reveals small-molecule targets in TOR pathway. Nat. Chem. Biol. 2, 103-109 (2006).
41. Hoon, S. et al. An integrated platform of genomic assays reveals small-molecule bioactivities. Nat. Chem. Biol. 4, 498-506 (2008).
42. Cherry, J. M. et al. SGD: Saccharomyces Genome Database. Nucleic Acids Res. 26, 73-79 (1998).
43. Finn, R. D. et al. Pfam: the protein families database. Nucleic Acids Res. 42, D222-D230 (2014).
44. Lage, K. et al. A large-scale analysis of tissue-specific pathology and gene expression of human disease genes and complexes. Proc. Natl. Acad. Sci. 105, 20870-20875 (2008).
45. Skrbo, A., Begovi?, B., Skrbo, S. [Classification of drugs using the ATC system (Anatomic, Therapeutic, Chemical Classification) and the latest changes]. Med. Arh. 58, 138-141 (2004).
46. Eden, E., Navon, R., Steinfeld, I., Lipson, D., Yakhini, Z. GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC Bioinformatics 10, 48 (2009).